CA3151821A1 - Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors - Google Patents

Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors Download PDF

Info

Publication number
CA3151821A1
CA3151821A1 CA3151821A CA3151821A CA3151821A1 CA 3151821 A1 CA3151821 A1 CA 3151821A1 CA 3151821 A CA3151821 A CA 3151821A CA 3151821 A CA3151821 A CA 3151821A CA 3151821 A1 CA3151821 A1 CA 3151821A1
Authority
CA
Canada
Prior art keywords
indazol
dihydrothieno
methy1
cyclopenta
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3151821A
Other languages
English (en)
French (fr)
Inventor
Shao-Zheng Peng
Chu-Bin Liao
Hung-Jyun HUANG
Yuan-Ting Cho
Yi-Mei CHANG
Yu-Chih PAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Development Center for Biotechnology
Original Assignee
Development Center for Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Development Center for Biotechnology filed Critical Development Center for Biotechnology
Publication of CA3151821A1 publication Critical patent/CA3151821A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3151821A 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors Pending CA3151821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891097P 2019-08-23 2019-08-23
US62/891,097 2019-08-23
PCT/US2020/047552 WO2021041276A1 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3151821A1 true CA3151821A1 (en) 2021-03-04

Family

ID=74685735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3151821A Pending CA3151821A1 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors

Country Status (11)

Country Link
US (1) US12448394B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017853A4 (cg-RX-API-DMAC7.html)
JP (1) JP7651557B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220051365A (cg-RX-API-DMAC7.html)
CN (1) CN114502553B (cg-RX-API-DMAC7.html)
AU (1) AU2020337883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151821A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002062A (cg-RX-API-DMAC7.html)
TW (1) TWI759829B (cg-RX-API-DMAC7.html)
WO (1) WO2021041276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113278010A (zh) * 2021-06-01 2021-08-20 中国科学院上海有机化学研究所 一类蛋白激酶降解剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
RU2425677C2 (ru) 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
EP1845974A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
BRPI0618011A2 (pt) * 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
WO2013142382A1 (en) * 2012-03-22 2013-09-26 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US8853207B2 (en) * 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN119792569A (zh) 2018-01-10 2025-04-11 财团法人生物技术开发中心 抗体protac偶联物

Also Published As

Publication number Publication date
CN114502553A (zh) 2022-05-13
AU2020337883B2 (en) 2025-08-28
WO2021041276A1 (en) 2021-03-04
EP4017853A4 (en) 2023-08-30
US12448394B2 (en) 2025-10-21
MX2022002062A (es) 2022-04-25
TWI759829B (zh) 2022-04-01
AU2020337883A1 (en) 2022-03-24
CN114502553B (zh) 2024-07-26
TW202115087A (zh) 2021-04-16
EP4017853A1 (en) 2022-06-29
US20220289759A1 (en) 2022-09-15
KR20220051365A (ko) 2022-04-26
JP7651557B2 (ja) 2025-03-26
BR112022003383A2 (pt) 2022-05-17
JP2022545019A (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
CA3087089C (en) Fused ring compounds
TWI875756B (zh) Cdk抑制劑
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
JP7175026B2 (ja) プロテインキナーゼ阻害剤としての1h-イミダゾ[4,5-h]キナゾリン系化合物
KR102281288B1 (ko) 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
CN113214287B (zh) Hpk1抑制剂及其使用方法
AU2010286569C1 (en) Compounds and compositions as protein kinase inhibitors
CN108368057B (zh) 作为erk抑制剂的吡唑并稠合的杂环化合物
CA2756568A1 (en) Kinase inhibitors and method of treating cancer with same
JP2021514373A (ja) Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体
TWI648266B (zh) 作為第iii型受體酪胺酸激酶抑制劑之喹㗁啉化合物
CN118201896A (zh) PI3K-α抑制剂和其使用方法
CA2834101A1 (en) Novel indole or indazole derivative or salt thereof
AU2022226671B2 (en) Aminopyrimidine compounds and methods of their use
AU2020337883B2 (en) Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors
RU2833004C2 (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
CA3201841A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2026102147A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
HK40057478A (en) Hpk1 inhibitors and methods of using same
HK40057478B (en) Hpk1 inhibitors and methods of using same

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240911

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250403

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250428

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250604

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250604

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250708

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250716

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251117

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260106

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260623

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260623